Revenue Growth (Q4 and Full Year)
Q4 2025 revenue was $68.3M, up ~4% YoY from $65.9M; full year 2025 revenue was $262.9M, up just over 2% YoY, reflecting stabilization across the retail footprint and contributions from new stores.
Improved Gross Profit and Q4 Margin Expansion
Q4 gross profit was $28.6M or 41.9% of revenue vs $25.4M or 38.6% in Q4 2024, driven by higher production volumes, better product quality and operational improvements at grower-processor facilities.
Material Adjusted EBITDA Improvement
Q4 adjusted EBITDA was $13.9M (20.4% margin) vs $8.0M (12.2%) in prior-year quarter; full year adjusted EBITDA rose to $50.3M from $46.2M with margin expanding to 19.1% from 17.9%.
Operational Turnaround at Grower-Processor Facilities
Average yield across the portfolio increased ~28% per square foot YoY in Q4; potency sustained in the mid- to upper-20% THCa range and improvements produced a more favorable product mix across retail and wholesale.
Strategic Retail Growth and Branded Mix
Retail store count increased from 38 to 42 (≈11% YoY) while headcount rose only ~4% (1,234 to ~1,288), demonstrating scaling efficiency; Jushi-branded products represented ~58% of retail revenue in Q4 vs 55% prior year.
Refinancing Strengthens Near-Term Liquidity
Completed a $160M first-lien secured term loan due 2029 (12.5% coupon) to fully repay near-term maturities (~$46M term loan and ~$86M second-lien notes), providing $13M of incremental liquidity, extended maturities and no equity dilution; CEO increased personal capital participation.
Regulatory Progress - Virginia Adult Use
Virginia adult-use legislation reconciled and sent to the governor; timeline: applications by Sept 1, 2026, licenses by Dec 1, 2026, retail sales expected Jan 1, 2027. Company expects to leverage existing cultivation, manufacturing and retail infrastructure with limited incremental capital.
Selective CapEx Discipline and 2026 Guidance
FY2025 CapEx was $16.1M (maintenance $4.8M, growth $11.3M). 2026 guidance: maintenance CapEx $4–5M; growth CapEx $5–8M; total projected $9–13M, reflecting disciplined capital allocation tied to regulatory clarity.